The "Undetermined Significance" of 18 F-FDG PET/CT or PET/MRI in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS)

Medicina (Kaunas). 2021 Aug 23;57(8):856. doi: 10.3390/medicina57080856.

Abstract

Monoclonal gammopathy of undetermined significance (MGUS) is a highly prevalent condition with the possible risk of progression to multiple myeloma (MM) or a lymphoproliferative neoplasm in a small percentage of patients. Fluorine-18 fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) or positron emission tomography/magnetic resonance imaging (PET/MRI) are imaging methods increasingly used in patients with MM. The aim of this communication is to underline that, taking into account current evidence-based data, compared to MM the role of 18F-FDG PET/CT or PET/MRI in MGUS is still undetermined and more studies should be performed before suggesting 18F-FDG PET/CT or PET/MRI for evaluation of MM progression in patients with MGUS.

Keywords: FDG; MGUS; PET; evidence-based; imaging; monoclonal gammopathy; myeloma; plasma cell; recommendation.

MeSH terms

  • Fluorodeoxyglucose F18*
  • Humans
  • Magnetic Resonance Imaging
  • Monoclonal Gammopathy of Undetermined Significance* / diagnostic imaging
  • Positron Emission Tomography Computed Tomography
  • Positron-Emission Tomography

Substances

  • Fluorodeoxyglucose F18